The Use of Xenotransplantation in Neurodegenerative Diseases: A Way to Go?

Lévèque, Xavier; Fink, Kyle D.; Rossignol, Julien; Dunbar, Gary; Lescaudron, Laurent

doi:10.5772/29805

Cited by 1 publication

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An ongoing challenge to the clinical development of stem cell therapies for HD and JHD is navigating the immune response to the transplant. Although the brain has often been considered an ‘immune privileged’ organ, there are several reported cases suggesting a strong immune response with the brain that can lead to the rejection of the graft and the subsequent halting of beneficial effects [138] While it has been suggested in previous work that MSC provide immune modulation in the area around the transplant, many of these studies use an allotransplantation paradigm, thus reducing the extent of neuroinflammation [139]. While this can be addressed by using species-specific cells to avoid rejection of the xenograft, this strategy includes several caveats that impede the clinical relevancy of these studies.…”

Section: Ongoing Challengesmentioning

confidence: 99%

Developing Stem Cell Therapies for Juvenile and Adult-Onset Huntington's Disease

et al. 2015

View full text Add to dashboard Cite

Stem cell therapies have been explored as a new avenue for the treatment of neurologic disease and damage within the CNS in part due to their native ability to mimic repair mechanisms in the brain. Mesenchymal stem cells have been of particular clinical interest due to their ability to release beneficial neurotrophic factors and their ability to foster a neuroprotective microenviroment. While early stem cell transplantation therapies have been fraught with technical and political concerns as well as limited clinical benefits, mesenchymal stem cell therapies have been shown to be clinically beneficial and derivable from nonembryonic, adult sources. The focus of this review will be on emerging and extant stem cell therapies for juvenile and adult-onset Huntington's disease.

show abstract

Section: Ongoing Challengesmentioning

confidence: 99%